These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

94 related items for PubMed ID: 7858530

  • 1. Short-term ex vivo activation of splenocytes with anti-CD3 plus IL-2 and infusion post-BMT into mice results in in vivo expansion of effector cells with potent anti-lymphoma activity.
    Katsanis E, Xu Z, Anderson PM, Dancisak BB, Bausero MA, Weisdorf DJ, Blazar BR, Ochoa AC.
    Bone Marrow Transplant; 1994 Oct; 14(4):563-72. PubMed ID: 7858530
    [Abstract] [Full Text] [Related]

  • 2. Antitumor effects of interleukin 2 liposomes and anti-CD3-stimulated T-cells against murine MCA-38 hepatic metastasis.
    Loeffler CM, Platt JL, Anderson PM, Katsanis E, Ochoa JB, Urba WJ, Longo DL, Leonard AS, Ochoa AC.
    Cancer Res; 1991 Apr 15; 51(8):2127-32. PubMed ID: 1826232
    [Abstract] [Full Text] [Related]

  • 3. Anti-CD3 + IL-2-stimulated murine killer cells. In vitro generation and in vivo antitumor activity.
    Anderson PM, Blazar BR, Bach FH, Ochoa AC.
    J Immunol; 1989 Feb 15; 142(4):1383-94. PubMed ID: 2521662
    [Abstract] [Full Text] [Related]

  • 4. In vivo antitumor activity of anti-CD3-induced activated killer cells.
    Yun YS, Hargrove ME, Ting CC.
    Cancer Res; 1989 Sep 01; 49(17):4770-4. PubMed ID: 2527087
    [Abstract] [Full Text] [Related]

  • 5. Ex vivo expansion of dendritic-cell-activated antigen-specific CD4+ T cells with anti-CD3/CD28, interleukin-7, and interleukin-15: potential for adoptive T cell immunotherapy.
    Chen HW, Liao CH, Ying C, Chang CJ, Lin CM.
    Clin Immunol; 2006 Apr 01; 119(1):21-31. PubMed ID: 16406844
    [Abstract] [Full Text] [Related]

  • 6. Low dose subcutaneous interleukin-2 after autologous transplantation generates sustained in vivo natural killer cell activity.
    Miller JS, Tessmer-Tuck J, Pierson BA, Weisdorf D, McGlave P, Blazar BR, Katsanis E, Verfaillie C, Lebkowski J, Radford J, Burns LJ.
    Biol Blood Marrow Transplant; 1997 Apr 01; 3(1):34-44. PubMed ID: 9209739
    [Abstract] [Full Text] [Related]

  • 7. Antitumor protection from the murine T-cell leukemia/lymphoma EL4 by the continuous subcutaneous coadministration of recombinant macrophage-colony stimulating factor and interleukin-2.
    Vallera DA, Taylor PA, Aukerman SL, Blazar BR.
    Cancer Res; 1993 Sep 15; 53(18):4273-80. PubMed ID: 8364923
    [Abstract] [Full Text] [Related]

  • 8. Nonmitogenic anti-CD3F(ab')2 fragments inhibit lethal murine graft-versus-host disease induced across the major histocompatibility barrier.
    Blazar BR, Taylor PA, Snover DC, Bluestone JA, Vallera DA.
    J Immunol; 1993 Jan 01; 150(1):265-77. PubMed ID: 8417127
    [Abstract] [Full Text] [Related]

  • 9. Preclinical studies for adoptive immunotherapy in bone marrow transplantation. Generation of anti-CD3 activated cytotoxic T cells from normal donors and autologous bone marrow transplant candidates.
    Ueda M, Joshi ID, Dan M, Uberti JP, Chou TH, Sensenbrenner LL, Lum LG.
    Transplantation; 1993 Aug 01; 56(2):351-6. PubMed ID: 8356589
    [Abstract] [Full Text] [Related]

  • 10. Effects of ex vivo activated immune cells on syngeneic and semi-allogeneic bone marrow transplantation in mice.
    Yang G, Tan J, Wei G, Deng Y, Chen H, Yang D.
    Transpl Immunol; 2006 Nov 01; 16(3-4):166-71. PubMed ID: 17138049
    [Abstract] [Full Text] [Related]

  • 11. Abrogation of graft-vs.-leukemia activity after depletion of CD3+ T cells in a murine model of MHC-matched peripheral blood progenitor cell transplantation (PBPCT).
    Uharek L, Glass B, Zeis M, Dreger P, Steinmann J, Löffler H, Schmitz N.
    Exp Hematol; 1998 Feb 01; 26(2):93-9. PubMed ID: 9472798
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. IL-4 regulation of perforin gene expression and BLT-esterase production in alpha CD3-induced activated killer cells.
    Ting CC, Liang SM, Wang J, Chen YY, Hargrove M, Xu N.
    Biotechnol Ther; 1998 Feb 01; 5(3-4):99-115. PubMed ID: 8608327
    [Abstract] [Full Text] [Related]

  • 14. Recombinant interleukin 2 stimulates in vivo proliferation of adoptively transferred lymphokine-activated killer (LAK) cells.
    Ettinghausen SE, Lipford EH, Mulé JJ, Rosenberg SA.
    J Immunol; 1985 Nov 01; 135(5):3623-35. PubMed ID: 3900213
    [Abstract] [Full Text] [Related]

  • 15. Construction and characterization of a novel fusion protein consisting of anti-CD3 antibody fused to recombinant interleukin-2.
    Lee KD, Chen HW, Chen CC, Shih YC, Liu HK, Cheng ML.
    Oncol Rep; 2006 May 01; 15(5):1211-6. PubMed ID: 16596189
    [Abstract] [Full Text] [Related]

  • 16. Regulation by glutathione of the effect of lymphokines on differentiation of primary activated lymphocytes. Influence of glutathione on cytotoxic activity of CD3-AK-.
    Liang SM, Liang CM, Hargrove ME, Ting CC.
    J Immunol; 1991 Mar 15; 146(6):1909-13. PubMed ID: 1826013
    [Abstract] [Full Text] [Related]

  • 17. In vivo or in vitro anti-CD3 epsilon chain monoclonal antibody therapy for the prevention of lethal murine graft-versus-host disease across the major histocompatibility barrier in mice.
    Blazar BR, Taylor PA, Vallera DA.
    J Immunol; 1994 Apr 01; 152(7):3665-74. PubMed ID: 8144942
    [Abstract] [Full Text] [Related]

  • 18. In vivo expansion of activated naive CD8+ T cells and NK cells driven by complexes of IL-2 and anti-IL-2 monoclonal antibody as novel approach of cancer immunotherapy.
    Tomala J, Chmelova H, Mrkvan T, Rihova B, Kovar M.
    J Immunol; 2009 Oct 15; 183(8):4904-12. PubMed ID: 19801515
    [Abstract] [Full Text] [Related]

  • 19. Neutralization of interleukin-2 retards the growth of mouse renal cancer.
    Fukuhara H, Matsumoto A, Kitamura T, Takeuchi T.
    BJU Int; 2006 Jun 15; 97(6):1314-21. PubMed ID: 16686731
    [Abstract] [Full Text] [Related]

  • 20. Endogenous and adoptively transferred A-NK and T-LAK cells continuously accumulate within murine metastases up to 48 h after inoculation.
    Hokland M, Kjaergaard J, Kuppen PJ, Nannmark U, Agger R, Hokland P, Basse P.
    In Vivo; 1999 Jun 15; 13(3):199-204. PubMed ID: 10459491
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.